China's medical electronics market industry income analysis

China's medical electronics market industry income analysis According to the analysis, with the promotion of a series of policies, it is expected that the revenue of China's medical electronics industry will grow by nearly double in five years from 2011.

In 2011, the revenue of China's medical electronics industry was 4 billion U.S. dollars, a year-on-year increase of 19.6%. It is estimated that in 2012 it will increase by 18.4% year-on-year, and by 2016 this market will reach US$7.4 billion, with a CAGR of 13%.

Specifically, the main policies to be motivated are the "Twelfth Five-Year Plan for Medical Device Technology Industry" published by the Ministry of Science and Technology in early 2012, and the "Health China 2020" strategic study released by the Ministry of Health in August, which states that by 2020, The total expenditure on public health in China will account for 6.5%-7% of GDP. “This size is equivalent to US$63.5 billion. Despite the uncertainties in the economic situation, the Chinese government will continue to increase subsidies to implement relevant policies,” said an expert analysis.

In addition, in response to China's 12th Five-Year Plan, first-tier medical electronics manufacturers plan to introduce cost equipment for second- and third-tier cities. At the same time, domestic manufacturers’ R&D investment is also increasing. Leading domestic manufacturers are realizing differentiated and enhanced brand influence through the introduction of advanced products to change their low-end positioning.

Experts believe that due to the strong demand for personal health monitoring, various types of home-portable medical devices have rapidly become popular products. It is predicted that in 2012, revenue from consumer medical equipment will grow to US$1.1 billion, which is an increase of 19% from 2011.

At the same time, China's consumer medical device market will use semiconductor devices worth approximately US$70 million in 2012, accounting for 28.5% of the total consumer scale. Due to the increasing importance of portability for medical devices, manufacturers are trying to reduce the design complexity and the time needed to develop finished products, and strive to increase the market share of China's medical electronics industry.

Clorsulon Injection

Losuron Clorsulon is an anti schistosomiasis drug, which can be used to treat schistosomiasis.
It is slightly harmful to water. Do not discharge materials into the surrounding environment without government permission.
Solubility (mg / ml): water: insoluble in water, soluble in most organic solvents.
Avoid contact with oxides.
It is used to treat Fasciola hepatica infection in calves and sheep.
Clorsulon is a competitive inhibitor of 3-phosphoglycerate and ATP with KI of 0.29 mm. It can inhibit the utilization of glucose and the formation of acetate and propionate in mature Fasciola hepatica in vitro.
Clorsulon (single dose 15 mg / kg) can effectively remove more than 90% of immature Fasciola hepatica in sheep (6 weeks after infection) and cattle (8 weeks after infection). The dose of 2.5 mg / kg can remove more than 90% of mature (16 week old) liver flukes in sheep. After in vivo cultivation, Clorsulon will seriously damage the cortex and viscera of Fasciola hepatica.

Injection 10% Clorsulon,Pharmaceutical Clorsulon Injection,100ml Clorsulon Injection,30% Injectable Clorsulon

Shandong Unovet Pharmaceutical Co.,Ltd. , https://www.unovetcn.com